CBFB::MYH11 inv(16) Detection, Quantitative
Also known as: INV 16 QNT
Use
This test is used to detect and quantitate CBFB::MYH11 fusion transcripts (type A, D, or E) resulting from inv(16) or t(16;16) chromosome rearrangements. It is particularly useful for monitoring minimal residual disease and assessing the risk of relapse in patients with acute myeloid leukemia, a condition characterized by such genetic abnormalities. Detecting these specific fusion transcripts can provide insights into the disease status and guide treatment decisions.
Special Instructions
Not provided.
Limitations
The test cannot detect translocations involving other genes or gene partners apart from those involving CBFB and MYH11. Uncommon transcripts other than type A, D, or E are not detectable with this assay. The limit of quantitation for this test is 0.0001 NCN, and results should always be interpreted in conjunction with other clinical data and patient history. Results from the test should not be solely relied upon for diagnosing malignancy as it might miss low-level disease below the detection limit.
New York Approved
Methodology
PCR-based (RT-qPCR)
Biomarkers
CBFB-MYH11 fusion
FusionCBFB-MYH11 Ratio fusion
Fusion
LOINC Codes
- 31208-2 - Specimen source
- 70291-0 - inv(16)(p13;q22) Bld/T Ql
- 72210-8 - inv(16)(p13;q22)/control Bld/T
Result Turnaround Time
5-9 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5 mL
Minimum Volume
3 mL
Container
EDTA
Storage Instructions
Refrigerate immediately after collection.
Causes for Rejection
Serum, plasma, extracted DNA, CSF, FFPE tissue, ambient whole blood, or frozen whole blood; specimens in anticoagulants other than EDTA; severely hemolyzed or clotted specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unacceptable |
| Refrigerated | 48 hours |
| Frozen | Unacceptable |
Other tests from different labs that may be relevant